Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose radiotherapy plus neoadjuvant tislelizumab and chemotherapy for locally advanced ESCC
ChiCTR2600121566Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathological complete response rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600121566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121566.